Inventiva: final analyses presented for LEGEND trial

(CercleFinance.com) - Inventiva reports the final analyses of its phase 2 proof-of-concept trial evaluating lanifibranor combined with empagliflozin in patients with steatohepatitis associated with metabolic dysfunction (MASH) and type 2 diabetes (T2DM).


The LEGEND study met its primary efficacy endpoint by significantly reducing HbA1c (Hemoglobin A1c) levels in the groups treated with lanifibranor alone or in combination with empagliflozin, compared with the placebo group.

Liver function tests, markers of hepatic fibrosis, as well as markers of cardiometabolic health, lipid profile and adiponectin levels, also showed improvement on lanifibranor alone or in combination.

The data will be presented this Monday, November 18 by poster at the 'late-breaker' session of the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place in San Diego, California.

Copyright (c) 2024 CercleFinance.com. All rights reserved.